Viewing Study NCT06445244



Ignite Creation Date: 2024-06-16 @ 11:51 AM
Last Modification Date: 2024-10-26 @ 3:31 PM
Study NCT ID: NCT06445244
Status: RECRUITING
Last Update Posted: 2024-06-06
First Post: 2024-05-31

Brief Title: α-ketoglutarate in Patients With Hypertension
Sponsor: Jun Tao
Organization: First Affiliated Hospital Sun Yat-Sen University

Study Overview

Official Title: The Effects of α-ketoglutarate on Blood Pressure and Endothelial Function in Hypertensive Patients
Status: RECRUITING
Status Verified Date: 2024-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: AKGHTN
Brief Summary: Cardiovascular and cerebrovascular diseases are most terrible killers endangering the health of Chinese residents and hypertension is the most important risk factor Hypertension related microvascular rarefaction and endothelial dysfunction are the common pathological basis and initiation of cardiovascular and cerebrovascular disease Therefore reducing blood pressure and delaying or reversing endothelial dysfunction is an effective way to treat hypertension and prevent cardiovascular disease Alpha-ketoglutarate αKG is a critical metabolic intermediate in the tricarboxylic acid TCA cycle involves in diverse cellular biological activities such as central metabolism antioxidative defense epigenetic regulation and cell proliferation The latest research found that with the growth of age the level of αKG is decreasing and increasing the content of αKG can prolong the life of multiple species including human Recent clinical trials found that αKG supplementation can effectively improve the level of αKG in cells delay aging improve the metabolic process of cells without adverse reactions However the effect of αKG supplementation on reducing blood pressure and protecting vascular endothelial function has not been reported Therefore this study aims to focus on hypertension a major chronic disease and to observe the effects of αKG supplementation on endothelial function and blood pressure in patients with hypertension so as to provide a new treatment strategy for hypertension and associated endothelial dysfunction
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?: None